Litigation charges weighed on Boston Scientific Corp.'s second quarter profits, but analysts seemed so impressed with the company's better-than-expected sales and 10 percent organic sales growth they barely mentioned the $207 million (15 cents a share) net loss in their reports. A year earlier, Boston Scientific posted a profit of $102 million (8 cents a share).